In keeping with the company’s intention to design drugs meeting
significant human health needs, oncology was selected as the therapeutic area for the
initial discovery program. The most advanced projects are in the area of estrogen receptor
modulators followed by projects in the area of angiogenesis. The antiestrogen project was
also chosen to demonstrate proof of principle for technology development.
